查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863425

脑部影像技术市场：2025-2032年全球预测（按影像方式、应用和最终用户划分）

Brain Imaging Modalities Market by Modality, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，脑造影技术市场将成长至 183.2 亿美元，复合年增长率为 6.58%。

主要市场统计数据
基准年 2024 109.9亿美元
预计年份：2025年 117.1亿美元
预测年份：2032年 183.2亿美元
复合年增长率 (%) 6.58%

对现代脑部造影技术进行了权威概述，并探讨了各种成像方式的融合如何重塑临床护理和神经科学研究的进程。

脑部影像研究已发展成为一门多学科交叉领域，涵盖临床神经病学、外科、神经科学研究和生物医学工程等多个学科。仪器设备、数据分析和示踪化学技术的进步，不仅拓展了可用的影像方式，也提高了临床医师诊断、监测和治疗神经系统疾病的精准度。因此，从急性介入方案的发展到长期治疗监测，再到基础机制研究，影像技术贯穿各个环节。

人工智慧、携带式设备、混合成像示踪剂和可互通分析技术的进步如何重塑临床实践、研究工作流程和诊断信心

在技​​术创新、资料科学和不断变化的临床需求的驱动下，脑造影领域正在发生许多变化。人工智慧和先进的影像分析技术正在与人类解读相辅相成，使人们能够发现以往难以检测的细微病理生理变化，并提取定量生物标记。同时，高场磁振造影系统、小型电脑断层扫描器和携带式超音波设备等硬体创新正在拓展施行地点，使诊断能力更贴近临床第一线。

评估2025年关税环境对脑部影像相关人员的供应可靠性、筹资策略和研究连续性的影响

2025年关税调整政策的实施对全球脑部影像硬体、耗材及配套服务的供应链产生了显着的连锁反应。对专用零件征收更高的进口关税延长了大型设备和间歇性零件的前置作业时间，促使製造商和医疗机构重新评估其筹资策略。因此，采购週期延长，资本规划中需要预留更多缓衝资金，以确保升级和安装工作按计画进行。

深度分割分析整合了模态差异、应用需求和最终用户限制，以指导采购、研发和临床实施策略。

研究结果揭示了不同成像方式、应用领域和最终用户维度上，技术采纳、临床效用和研究投入的微妙模式。影像方式包括电脑断层扫描（CT）、磁振造影）、光学影像、正子断层扫描（PET）、单光子发射电脑断层扫描（SPC）和超音波影像。在CT领域，锥状射束和传统系统之间的差异会影响介入和手术导航的选择。同时， 磁振造影分为血管造影术、扩散影像、功能性影像和结构影像技术，分别用于血管、白质、功能连结和解剖结构评估。同样，光学成像包括功能性近红外线光谱和光同调断层扫瞄）。正子断层扫描可以区分淀粉样蛋白、多巴胺和FDG等追踪剂，而SPC通常用于多巴胺转运体成像。超音波成像技术目前分为两大类：生物显微镜用于高解析度眼部和浅表组织成像，经颅都卜勒用于血流动力学监测。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 超强磁场7T和11.7T磁振造影扫描仪的出现，使得大脑解析度达到了前所未有的水平。
  • 将人工智慧和深度学习演算法相结合用于高级神经影像分析
  • 开发用于全面功能和结构成像的PET/MRI和SPECT/CT混合系统
  • 携带式照护现场脑电图和功能近红外光谱设备在即时神经监测中的广泛应用
  • 扩大定量影像生物标记在评估神经退化性疾病进展的应用
  • 核磁共振导引聚焦超音波技术在非侵入性神经调控和标靶治疗的应用进展
  • 推出云端基础的远距脑部造影和远端医疗解决方案平台
  • 更特异性的分子脑部影像诊断放射性药物和示踪剂的创新
  • 采用运动校正和高速成像技术来减少扫描时间伪影
  • 精神疾病与认知障碍研究中对功能连结图谱的需求日益增长

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 脑部影像模式市场（依模式划分）

  • 电脑断层扫描
    • 锥状射束
    • 传统的
  • 磁振造影
    • 血管造影术
    • 扩散
    • 功能性
    • 结构
  • 光学成像
    • FNIrS
    • 光同调断层扫瞄
  • 正子断层扫描
    • 淀粉样蛋白
    • 多巴胺
    • FDG
  • 单光子发射电脑断层扫描
    • 多巴胺转运体
  • 超音波成像
    • 活体显微镜
    • 经颅都卜勒

第九章 依应用分類的脑部影像方式市场

  • 诊断
    • 癫痫
    • 神经退化性疾病
    • 创伤性脑损伤
    • 肿瘤检测
    • 血管疾病
  • 研究
    • 脑图谱
    • 神经科学
      • 基础研究
      • 临床研究
    • 药物研发
  • 治疗监测
    • 疾病进展追踪
    • 手术监测
    • 治疗效果评估

第十章 依最终用户分類的脑部影像方式市场

  • 学术机构
    • 医学院
    • 大学
  • 门诊护理设施
  • 诊断中心
  • 居家医疗
  • 医院
  • 研究所
    • 政府实验室
    • 私人实验室

第十一章 各地区脑造影技术市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 脑部影像方式市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国脑部影像技术市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Siemens Healthineers AG
    • General Electric Company
    • Koninklijke Philips NV
    • Canon Inc.
    • Hitachi Ltd.
    • Fujifilm Holdings Corporation
    • Shimadzu Corporation
    • Neusoft Medical Systems Co., Ltd.
    • Samsung Electronics Co., Ltd.
    • Bruker Corporation
Product Code: MRR-5C6F41F5AF90

The Brain Imaging Modalities Market is projected to grow by USD 18.32 billion at a CAGR of 6.58% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.99 billion
Estimated Year [2025] USD 11.71 billion
Forecast Year [2032] USD 18.32 billion
CAGR (%) 6.58%

An authoritative overview of contemporary brain imaging technologies and how convergence of modalities is reshaping clinical care and neuroscience research pathways

The study of brain imaging has matured into a multidisciplinary field that sits at the intersection of clinical neurology, surgical practice, neuroscience research, and biomedical engineering. Advances in instrumentation, data analytics, and tracer chemistry have expanded the portfolio of available modalities while elevating the clinical precision with which clinicians diagnose, monitor, and treat neurological disorders. As a result, imaging now informs everything from acute intervention planning to long-term therapeutic monitoring and basic mechanistic inquiry.

Technological refinements have driven improvements in spatial and temporal resolution, reduced acquisition times, and enabled safer, more patient-centric workflows, which in turn facilitate broader clinical adoption. Simultaneously, the proliferation of multimodal imaging approaches and integrated analytical pipelines has created new opportunities for cross-disciplinary collaboration, allowing clinicians and researchers to combine structural, functional, molecular, and hemodynamic information in a single diagnostic narrative. Consequently, imaging is increasingly central to personalized care pathways and to translational research paradigms that aim to close the gap between bench and bedside.

Looking ahead, implementation of scalable data standards, validation frameworks, and interoperable platforms will determine how rapidly new technologies translate into routine clinical use. With attention to regulatory compliance, reimbursement patterns, and clinician training, organizations can navigate the complexity of modality choice, clinical indication, and operational constraints to deliver measurable improvements in diagnostic accuracy and patient outcomes.

How advances in AI, portable instrumentation, hybrid imaging tracers, and interoperable analytics are reshaping clinical practice, research workflows, and diagnostic confidence

A number of transformative shifts are reconfiguring the brain imaging landscape, driven by technological innovation, data science, and evolving clinical needs. Artificial intelligence and advanced image analytics now augment human interpretation, enabling improved detection of subtle pathophysiology and the extraction of quantitative biomarkers that were previously inaccessible. At the same time, hardware innovation-such as higher field magnetic resonance systems, compact computed tomography units, and portable ultrasound-has expanded where and how imaging can be delivered, moving diagnostic capability closer to point-of-care settings.

Concurrently, molecular imaging tracers and hybrid systems have refined the capacity for in vivo biochemical mapping, which enhances diagnostic specificity for conditions such as neurodegenerative disease and focal epileptogenic zones. Integration between structural and functional modalities supports more accurate surgical planning and targeted therapeutic monitoring, while optical techniques have opened non-invasive windows for bedside neurovascular and hemodynamic assessment. As interoperability standards and cloud-native platforms mature, multi-site data aggregation increases the statistical power of research studies and accelerates clinical validation of novel biomarkers.

Consequently, stakeholders must adapt to an environment where technological choices are inseparable from data governance, clinical workflow redesign, and workforce competency. Providers that invest in scalable infrastructure, validate AI tools against robust ground truth, and cultivate multidisciplinary teams will capture the greatest clinical and operational value from these shifts.

Assessment of how the 2025 tariff environment reshaped supply reliability, procurement strategies, and research continuity for brain imaging stakeholders

Policy shifts enacted through tariff changes in 2025 created pronounced ripple effects across the global supply chain for brain imaging hardware, consumables, and ancillary services. Increased import duties on specialized components elevated lead times for large equipment and intermittent components, prompting manufacturers and health systems to reassess sourcing strategies. As a result, procurement cycles lengthened and capital planning required greater contingency buffering to maintain scheduled upgrades and installations.

Moreover, tariffs had heterogeneous effects across product categories. High-precision manufacturing elements used in computed tomography gantries, magnetic resonance gradient systems, and PET/SPECT detectors experienced supply pressure, whereas software and digital services, which predominantly travel electronically, were less directly affected. Consequently, some providers prioritized modular upgrades and software-driven improvements as near-term mitigations while deferring hardware refreshes. Research institutions were particularly sensitive to customs delays affecting radiochemistry kits and tracers used in molecular imaging, which complicated study timelines and regulatory submissions.

In response, industry actors accelerated diversification of manufacturing footprints, increased inventory of critical spares, and expanded regional partnerships to localize production where feasible. Simultaneously, strategic collaboration between device manufacturers, logistics providers, and clinical purchasers became essential to ensure continuity of service and to protect sensitive research schedules. Going forward, adaptations in procurement strategy, contract design, and supply chain visibility will remain central to managing policy-driven disruptions.

Deep segmentation insights synthesizing modality differences, application needs, and end-user constraints to guide procurement, R&D, and clinical deployment strategies

Segmentation-driven insights reveal nuanced patterns of adoption, clinical utility, and research allocation across modality, application, and end user dimensions. Based on modality, the landscape includes Computed Tomography, Magnetic Resonance Imaging, Optical Imaging, Positron Emission Tomography, Single Photon Emission Computer Tomography, and Ultrasound Imaging; within Computed Tomography, distinctions between Cone Beam and Conventional systems influence choices for interventional and surgical guidance, whereas Magnetic Resonance Imaging subdivides into Angiography, Diffusion, Functional, and Structural techniques that support vascular, white matter, functional connectivity, and anatomical assessments. Similarly, Optical Imaging encompasses functional near-infrared spectroscopy and optical coherence tomography, and Positron Emission Tomography differentiates among tracers such as amyloid, dopamine, and FDG, with Single Photon Emission Computer Tomography frequently focused on dopamine transporter imaging. Ultrasound Imaging remains bifurcated between biomicroscopy for high-resolution ocular and superficial tissue applications and transcranial Doppler for hemodynamic monitoring.

Based on application, the primary categories encompass Diagnostics, Research, and Therapeutic Monitoring; diagnostic subdomains include epilepsy, neurodegenerative disorders, traumatic brain injury, tumor detection, and vascular disease, each demanding specific modality strengths and tailored acquisition protocols. The research domain spans brain mapping, neuroscience, and pharmaceutical development, with neuroscience further divided into basic and clinical research, highlighting distinct validation, reproducibility, and ethics considerations. Therapeutic monitoring focuses on disease progression tracking, surgical monitoring, and treatment response assessment, where longitudinal consistency and biomarker robustness are critical to clinical decision making.

Based on end user, the ecosystem comprises academic institutions, ambulatory care facilities, diagnostic centers, home healthcare, hospitals, and research institutes; academic institutions further include medical schools and universities, while research institutes encompass government and private lab operators. Each end user has unique capital constraints, workflow needs, and regulatory exposures that shape procurement priorities. For example, academic and research settings prioritize flexible, high-throughput platforms and data accessibility for hypothesis generation, whereas hospitals emphasize integrated PACS, streamlined workflows, and reimbursement alignment for routine diagnostic throughput. Ambulatory and home care settings increasingly adopt compact and portable options that support decentralized patient pathways, and diagnostic centers balance cost efficiency with specialization to attract referral traffic.

Taken together, these segmentation layers demonstrate that modality choice cannot be decoupled from clinical indication, operational context, or end-user constraints. Stakeholders should therefore align procurement and development strategies to the specific demands of the modality-application-end user nexus to maximize clinical impact and operational efficiency.

Regional strategic considerations emphasizing how adoption, regulation, infrastructure, and supply chain localization differ across the Americas, EMEA, and Asia-Pacific

Regional dynamics shape adoption curves, regulatory timelines, infrastructure investment, and supply chain resilience in distinct ways across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinical consolidation, high levels of private investment, and established reimbursement pathways support rapid uptake of advanced imaging capabilities, particularly in tertiary hospital settings and research hubs. Conversely, this region also faces pressures from capital cycle optimization and an increased emphasis on value-based procurement, which drives interest in solutions that demonstrate clear outcomes and operational efficiencies.

In Europe Middle East & Africa, heterogeneous regulatory landscapes and variable infrastructure maturity lead to differentiated adoption patterns. Western European centers continue to lead in high-field MRI and molecular imaging applications, supported by integrated clinical research networks, while pockets in the Middle East and Africa show targeted investments in imaging infrastructure aimed at building regional centers of excellence. Cross-border collaboration and harmonized clinical trials are increasingly important, and stakeholders must navigate a patchwork of reimbursement regimes and data protection requirements to scale solutions continentally.

Asia-Pacific displays a dynamic mix of rapid technology adoption in urban tertiary centers, government-led modernization programs, and an expanding landscape of domestic manufacturers. High patient volumes accelerate innovation in throughput optimization and cost-effective imaging solutions, and regulatory bodies are increasingly aligning with international standards to support clinical trials and cross-jurisdictional device approval. Across all regions, local workforce training, supply chain localization, and culturally tailored clinical pathways remain critical to sustaining adoption and maximizing health system impact.

How corporate strategies, partnerships, and platform approaches are converging to accelerate validation and commercial adoption of advanced brain imaging solutions

Corporate behavior in the brain imaging ecosystem reflects a blend of capability consolidation, strategic partnerships, and targeted innovation aimed at closing clinical gaps. Established device manufacturers continue to prioritize integration of advanced image processing, AI-augmented interpretation, and service models that bundle equipment with lifecycle support. At the same time, specialized vendors and start-ups concentrate on niche capabilities such as tracer development, optical imaging modules, or advanced post-processing analytics, carving out value by addressing unmet clinical or research needs.

Partnerships between hardware suppliers, software developers, and clinical centers accelerate validation pathways and reduce time to adoption. These collaborations often include co-development agreements, joint clinical validation studies, and shared data access arrangements that facilitate regulatory submissions and broaden the evidence base. In parallel, companies are increasingly exploring as-a-service commercial models to lower barriers to adoption and to create recurring revenue streams that align vendor incentives with clinical outcomes.

Finally, corporate strategies that emphasize open platforms, interoperable standards, and clinician-centric workflows tend to achieve stronger adoption in complex health systems. Organizations that invest in transparent evidence generation, robust post-market surveillance, and scalable customer support position themselves to capture long-term value as imaging becomes more central to personalized neurology and translational research.

Practical, high-impact recommendations for executives and clinical leaders to strengthen resilience, validate innovations, and accelerate safe adoption of imaging advances

Industry leaders should adopt a pragmatic, action-oriented playbook that balances near-term operational resilience with long-term clinical innovation. First, diversify procurement and manufacturing relationships to reduce exposure to supply chain shocks and policy shifts, while simultaneously investing in inventory visibility tools that enable anticipatory sourcing. Second, prioritize interoperability and standards compliance when selecting imaging hardware and software to protect future investment and to streamline multi-site research collaborations.

Third, integrate AI and analytics through rigorous validation pipelines that include independent clinical testing, explainability assessments, and continuous performance monitoring in real-world settings. Fourth, align product development and clinical implementation with clear use case definitions and outcome metrics so that value can be demonstrated to payers and health system decision makers. Fifth, commit to workforce development by funding clinician training programs and cross-disciplinary teams that bridge radiology, neurology, and data science; this will accelerate uptake and ensure safe, effective utilization.

Lastly, pursue collaborative models that involve clinicians early in product design, leverage public-private partnerships for tracer and protocol development, and explore innovative commercial frameworks such as outcome-linked agreements. By taking these actions, organizations will be better positioned to convert technological advances into sustainable clinical and commercial value.

An integrated, multi-method research framework combining literature synthesis, expert interviews, device evidence, and scenario analysis to inform strategic decisions

The underlying research approach integrates multiple evidence streams to yield a robust and defensible analysis of the brain imaging landscape. Primary methodologies include systematic review of peer-reviewed literature, regulatory filings, and clinical trial registries, complemented by structured interviews with clinical experts, imaging scientists, procurement officers, and technology vendors. The synthesis draws on device performance specifications, tracer chemistry reports, and operational case studies to map technology capabilities to clinical and research use cases.

Data triangulation is a central pillar of the method, combining qualitative expert insight with quantitative indicators such as equipment deployment patterns, trial enrollment distributions, and citation-based scholarly activity. Scenario analysis is used to assess the implications of external drivers-such as policy shifts, reimbursement changes, and supply chain disruptions-while sensitivity assessments identify which variables have the greatest operational impact under alternative assumptions. Finally, ethical, regulatory, and data governance considerations are evaluated to ensure that recommendations are aligned with prevailing clinical standards and patient safety norms.

A concise synthesis of technological advances, operational imperatives, and strategic priorities that will determine clinical and research success in brain imaging

In summary, advances in imaging hardware, tracer chemistry, and analytics are collectively expanding the diagnostic and research capabilities available to clinicians and scientists. These advances create opportunities for more precise disease characterization, improved surgical planning, and robust therapeutic monitoring, but they also demand intentional investments in interoperability, validation, and workforce readiness. Policy developments and supply chain shifts emphasize the need for diversified procurement strategies and for closer collaboration between vendors and clinical operators.

For stakeholders across hospitals, research institutes, and commercial organizations, the imperative is to translate technological potential into reproducible clinical value through disciplined evidence generation and patient-centered implementation. By focusing on validated use cases, standardized data practices, and multisector partnerships, organizations can deploy imaging innovations that improve outcomes, reduce diagnostic uncertainty, and support translational research agendas. The future of brain imaging will be defined less by individual technologies and more by the systems that integrate them safely, efficiently, and equitably.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of ultra-high-field 7T and 11.7T MRI scanners enabling unprecedented brain resolution
  • 5.2. Integration of artificial intelligence and deep learning algorithms for advanced neuroimaging analysis
  • 5.3. Development of hybrid PET/MRI and SPECT/CT systems for comprehensive functional and structural mapping
  • 5.4. Expansion of portable and point-of-care EEG and fNIRS devices for real-time neurological monitoring
  • 5.5. Growing use of quantitative imaging biomarkers to assess neurodegenerative disease progression
  • 5.6. Advancements in MR-guided focused ultrasound for non-invasive neuromodulation and targeted therapy
  • 5.7. Adoption of cloud-based platforms and telemedicine solutions for remote brain imaging consultation
  • 5.8. Innovation in radiopharmaceuticals and tracers for more specific molecular brain imaging diagnostics
  • 5.9. Implementation of motion correction and accelerated imaging techniques to reduce scan time artifacts
  • 5.10. Increased demand for functional connectivity mapping in psychiatric and cognitive disorder research

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Imaging Modalities Market, by Modality

  • 8.1. Computed Tomography
    • 8.1.1. Cone Beam
    • 8.1.2. Conventional
  • 8.2. Magnetic Resonance Imaging
    • 8.2.1. Angiography
    • 8.2.2. Diffusion
    • 8.2.3. Functional
    • 8.2.4. Structural
  • 8.3. Optical Imaging
    • 8.3.1. Fnirs
    • 8.3.2. Optical Coherence Tomography
  • 8.4. Positron Emission Tomography
    • 8.4.1. Amyloid
    • 8.4.2. Dopamine
    • 8.4.3. Fdg
  • 8.5. Single Photon Emission Computer Tomography
    • 8.5.1. Dopamine Transporter
  • 8.6. Ultrasound Imaging
    • 8.6.1. Biomicroscopy
    • 8.6.2. Transcranial Doppler

9. Brain Imaging Modalities Market, by Application

  • 9.1. Diagnostics
    • 9.1.1. Epilepsy
    • 9.1.2. Neurodegenerative Disorders
    • 9.1.3. Traumatic Brain Injury
    • 9.1.4. Tumor Detection
    • 9.1.5. Vascular Disease
  • 9.2. Research
    • 9.2.1. Brain Mapping
    • 9.2.2. Neuroscience
      • 9.2.2.1. Basic Research
      • 9.2.2.2. Clinical Research
    • 9.2.3. Pharmaceutical Development
  • 9.3. Therapeutic Monitoring
    • 9.3.1. Disease Progression Tracking
    • 9.3.2. Surgical Monitoring
    • 9.3.3. Treatment Response Assessment

10. Brain Imaging Modalities Market, by End User

  • 10.1. Academic Institutions
    • 10.1.1. Medical Schools
    • 10.1.2. Universities
  • 10.2. Ambulatory Care Facilities
  • 10.3. Diagnostic Centers
  • 10.4. Home Healthcare
  • 10.5. Hospitals
  • 10.6. Research Institutes
    • 10.6.1. Government Labs
    • 10.6.2. Private Labs

11. Brain Imaging Modalities Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Brain Imaging Modalities Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Brain Imaging Modalities Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Siemens Healthineers AG
    • 14.3.2. General Electric Company
    • 14.3.3. Koninklijke Philips N.V.
    • 14.3.4. Canon Inc.
    • 14.3.5. Hitachi Ltd.
    • 14.3.6. Fujifilm Holdings Corporation
    • 14.3.7. Shimadzu Corporation
    • 14.3.8. Neusoft Medical Systems Co., Ltd.
    • 14.3.9. Samsung Electronics Co., Ltd.
    • 14.3.10. Bruker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRAIN IMAGING MODALITIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. BRAIN IMAGING MODALITIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN IMAGING MODALITIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE TRANSPORTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE TRANSPORTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE TRANSPORTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE TRANSPORTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE TRANSPORTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE TRANSPORTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-